LifeStance Health Group, Inc.
LFST · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.69 | 0.94 | 0.19 | -0.38 |
| FCF Yield | 3.07% | -2.00% | -1.51% | -2.73% |
| EV / EBITDA | 78.37 | -31.54 | -14.80 | -13.03 |
| Quality | ||||
| ROIC | -1.62% | -8.72% | -9.55% | -14.58% |
| Gross Margin | 32.17% | 28.62% | 27.57% | 30.19% |
| Cash Conversion Ratio | -1.87 | 0.09 | -0.24 | -0.03 |
| Growth | ||||
| Revenue 3-Year CAGR | 13.33% | 16.51% | 31.59% | 46.45% |
| Free Cash Flow Growth | 249.28% | -116.90% | 68.89% | -82.56% |
| Safety | ||||
| Net Debt / EBITDA | 8.29 | -4.12 | -2.58 | -0.04 |
| Interest Coverage | -1.19 | -8.91 | -10.55 | -7.36 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 12.24 |
| Cash Conversion Cycle | 35.41 | 32.20 | 28.82 | 73.04 |